Review

Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers

Robert G. Frykberg

Diabetic Foot Consultants, LLC, Midwestern University, Glendale, AZ 85308, USA; rgfdpm@diabeticfoot.net

Abstract: Oxygen is a critical component of many biological processes and is essential for wound healing. Chronic wounds are typically characterized as being hypoxic in that the partial pressure of oxygen (pO\textsubscript{2}) in the center of the wound is often below a critical threshold necessary to fully support those enzymatic processes necessary for tissue repair. Providing supplemental oxygen can effectively raise pO\textsubscript{2} levels to better optimize functioning of these essential enzymes. While hyperbaric oxygen therapy has been well studied in this regard, comparative clinical studies have fallen short of providing clear evidence in support of this modality for healing chronic diabetic foot ulcers (DFU). Topical oxygen therapy (TOT) has been in clinical use for over 50 years with encouraging pre-clinical and clinical studies that have shown improved healing rates when compared to standard care. Nonetheless, TOT has heretofore been discounted as an unproven wound healing modality without theoretical or clinical evidence to support its use. This review shall provide a brief summary of the role of oxygen in wound healing and, specifically, discuss the different types of topical oxygen devices and associated studies that have convincingly shown their efficacy in healing chronic DFUs. The time has come for topical oxygen therapy to be embraced as a proven adjunctive modality in this regard.

Keywords: oxygen; topical oxygen therapy; diabetic foot ulcers; wound healing

1. Introduction

While many clinicians might consider topical oxygen therapy (TOT) to be an unproven or controversial wound healing modality, it has been in clinical use for over fifty years. In his 1969 publication, Fischer described his novel topical “hyperbaric” oxygen system used to treat a variety of chronic wounds in an in-patient environment [1]. Using humidified oxygen under a constant pressure of 22 mmHg for 4–12 h per day, he was able to achieve success in 88% of his cases including diabetic foot ulcers (DFU), venous leg ulcers (VLU), and various decubitus pressure ulcers. In a subset of six patients with bilateral lesions using one side as a control, only the six “hyperbaric oxygen” treated wounds healed within 3 to 17 days. When the unhealed control wounds were subsequently switched to topical oxygen therapy, they all healed within 6 weeks. While this rudimentary case series was not up to the scientific standards of present-day clinical investigations, it was certainly compelling enough to lead to further applications for topically applied oxygen therapies.

Most unfortunately, almost 20 years later, the misleading TOT clinical trial by Leslie et al. was published in 1988 [2]. Often cited as the “evidence” to prove that topical oxygen therapy is not effective in healing DFU (or any other chronic wound), this clinical trial was a distortion of what might be considered a reasonable randomized controlled trial. The investigators enrolled only 28 patients, administered the topical “hyperbaric” oxygen (THO) therapy for only 2 weeks, and assessed primary healing outcomes of the DFU at 14 days. To expect to test the efficacy of any therapy within a short two-week period in a very underpowered study is, in itself, an exercise in futility. Although both groups, as compared to baseline, had significant reductions in wound area and depth by day 14, there were no differences between the two groups for these parameters. The authors therefore
concluded that healing of DFU was not accelerated by THO in their study. Sadly, this very poorly designed study led to many misconceptions about the utility of topical oxygen therapy for managing chronic wounds for several decades. Systemically administered hyperbaric oxygen therapy (HBOT), in contrast to TOT, has been well studied and embraced by the wound healing communities world-wide [3]. Although the putative physiologic benefits of HBOT are indeed compelling, clinical trials aimed at supporting its efficacy in healing chronic DFU have been contradictory and disappointing [4–6].

This review aims to briefly explore the role of oxygen in the healing wound and, specifically, to address the evidence supporting the benefits and clinical efficacy of TOT for healing chronic diabetic foot ulcers.

Oxygen and Wound Healing

Recognizing that Oxygen (O\textsubscript{2}) is required for almost every step of the response to the injury and wound healing cascade, several recent reviews have focused not only on the role of molecular oxygen in this regard but also on cellular and biochemical mechanisms for O\textsubscript{2} generation [3,7–10]. Chronic wounds are typically characterized as being hypoxic in that the partial pressure of oxygen (pO\textsubscript{2}) in the center of the wound is often below a critical threshold necessary to fully support those enzymatic processes necessary to regenerate tissue [10]. Disrupted vascular supply, chronic inflammation, bacterial overload, and exhausted local metabolic oxygen production all contribute to chronic hypoxia. While acute, short-term hypoxia can indeed be a stimulus for angiogenesis, chronic hypoxia impedes not only angiogenesis but also the associated generation of reactive oxygen species (ROS) necessary for the upregulation of growth factors, cell signaling, and bacterial killing [3]. Oxygen is the rate limiting substrate for numerous biochemical reactions and plays a crucial role in energy production and cellular metabolism. Molecular oxygen is, of course, also necessary for the synthesis of nitric oxide (NO) that regulates vasodilatation. Oxygen-dependent processes, so relevant in wound healing, include mitochondrial-driven adenosine triphosphate (ATP) production for chemical/cellular energy and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase for the production of ROS (“respiratory burst”) involved in signal transduction of growth factors, cellular recruitment, and bacterial killing [8–11]. The two most prevalent ROS, superoxide and hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}), both serve to upregulate the release of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) that stimulate endothelial cell division and migration to initiate angiogenesis, lymphocyte/leukocyte migration, and fibroblast division and migration to synthesize new extracellular matrix (ECM). ROS driven phagocytosis and bacterial killing by bacteriostatic H\textsubscript{2}O\textsubscript{2} release by platelets and neutrophils also play an important role in the initial clearing of bacterial pathogens [9] (Table 1).

Collagen synthesis, deposition, and polymerization can only take place provided there is the necessary molecular oxygen present for the hydroxylation of proline and lysine. Prolyl hydroxylase and lysyl hydroxylase are oxygen dependent and very sensitive to local pO\textsubscript{2} levels, with maximal activity at oxygen levels approaching 250 mmHg [8,10]. Since the pO\textsubscript{2} in the center of a chronic wound can be as low as 10 mmHg, maximal enzymatic activity and collagen production can only be achieved by increasing oxygen concentrations above normal physiologic levels. In fact, this is also true for NADPH oxidase where maximal ROS production occurs at oxygen levels approaching 300 mmHg [8,12]. Supplemental oxygen should therefore augment all of the biological processes necessary for healing by raising the pO\textsubscript{2} above those levels found not only in chronic wounds but also above normal tissue levels of 100 mmHg. The question remains, however, is there sufficient evidence to support a positive tissue response from topically applied oxygen?
Table 1. Role of Oxygen in Wound Healing.

| Oxygen-Dependent Product | Enzyme or Substrate                        | Function                                      | Cytokine, Cell Mediators; or Cellular/Tissue Effect |
|--------------------------|-------------------------------------------|-----------------------------------------------|---------------------------------------------------|
| ATP                      | ATP synthase, Cytochrome C, Electronic Transport Chain | Chemical Energy for metabolism                | Cell division and migration.                      |
|                          |                                           |                                               | Upregulation of Growth Factors (VEGF, PDGF, etc.) |
|                          |                                           |                                               | (leukocyte migration and phagocytosis, bacteriostatic) |
|                          |                                           |                                               | H$_2$O$_2$                                         |
|                          |                                           |                                               | VEGF, PDGF, NO, etc.                               |
| Reactive Oxygen Species  | NADPH oxidase                             | Cellular Signaling/transduction                |                                                   |
| (ROS)                    |                                           | Bacterial defenses                             |                                                   |
| “respiratory burst”      |                                           | Angiogenesis                                   |                                                   |
| (Superoxide, Hydrogen peroxide (H$_2$O$_2$)) |                                           |                                               |                                                   |
| Collagen synthesis       | Prolyl hydroxylase, lysyl hydroxylase     | Collagen deposition and crosslinking          | Fibroblasts                                       |
| Nitric oxide (NO)        | Nitric oxide synthase                     | Vasodilatation, angiogenesis                  | Endothelium                                       |

NADPH: nicotinamide adenine dinucleotide phosphate; VEGF: vascular endothelial growth factor; PDGF: platelet derived growth factor.

2. Topical Oxygen Devices

Topical oxygen therapy (TOT) can be defined as the administration of oxygen applied topically over injured tissue by either continuous diffusion or pressurized systems. Although there are dressings, gels, and hemoglobin sprays that can provide for oxygen release when applied to wounds, for the purposes of this discussion only mechanical devices specifically indicated for topical oxygen therapy will be discussed herein [3].

There are three general types of physical delivery systems for TOT: (1) those providing for continuous delivery of oxygen (CDO) (TransCu O$_2$® (EO2 Concepts); EpiFlo® (Ogenix); and Natrox® (Inotec), (2) those providing low constant pressure in a contained chamber (GRW Medical (Chadds Ford, PA, USA), OxyCare® (Bremen, Germany) and (3) those that are cyclically pressurized and humidified in a contained chamber [TWO2® (AOTI, Galway, Ireland) (Figure 1). CDO devices apply topical continuous diffusion of non-pressurized (normobaric) pure oxygen through small cannulas or thin tubes to semi-occlusive or proprietary wound dressings. Small portable, battery powered, electrochemical oxygen generators supply a continuous flow of pure oxygen over the wounds 24 h per day at a flow rate of up to 15 mL/h [13–15]. An oxygen gradient then develops between the overlying dressing and the wound bed, thereby facilitating oxygen diffusion. The wound dressings are typically changed weekly, and the oxygen generators (or batteries) are generally replaced after 1 to 2 weeks of continuous use. These light-weight devices can be held in a small pouch affixed to the patient’s leg or hip and allow for unrestricted ambulation within the prescribed offloading devices. There have been several recently published randomized controlled trials (RCT) that attest to their ease of use and positive effect on DFU wound healing [15–18].

The lower constant pressure devices provide oxygen delivery in a simple plastic boot that is placed over the extremity with the ulcer. One hundred percent oxygen is delivered for 90 min for 4 consecutive days per week. Constant pressure is then maintained within the chamber up to 22 mmHg (1.03 atm). Although less widely used than the other modalities, numerous studies have been conducted on these types of devices over the last four decades that have shown good clinical efficacy. However, the majority of these studies have consisted of case series or uncontrolled trials, including one animal study [19–21]. The one very poorly conducted RCT that used a similar device has been previously discussed [2]. A more recent retrospective chart review of a variety of non-healing wounds in patients from the manufacturer’s database reported that >50% of wounds less than 1 year in duration experienced healing [22].
## Continuous Diffusion (CDO)

| Feature                                                                 | Example       | Notes                                                                 |
|-------------------------------------------------------------------------|---------------|-----------------------------------------------------------------------|
| Variable Healing in UT-1A wounds shown in 3 RCTs to date                | EPIFLO, EO2,  | One database retrospective review and no recent controlled studies     |
|                                                                         | NATROX        | Recent Sham controlled RCT in DFU                                     |
|                                                                         |               | Shows 4x healing rate vs. SOC/sham                                     |
|                                                                         |               |                                                                       |
| Several case series                                                     | Mostly low level case series                                   | Multiple controlled studies in DFU and VLU showing efficacy           |
| Low continuous flow of O₂ (3–15 mL/h)                                  |               | High O₂ flow rate and deeper O₂ penetration into wound bed            |
|                                                                         |               | Higher diffusion gradient                                             |
| Sealed, Disposable Dressing                                            |               | Cyclical pressure reduces edema and stimulates angiogenesis           |
| Low O₂ PP Diffusion Gradient                                            |               |                                                                       |
| No compression or humidification                                        |               |                                                                       |
| Can macerate wound                                                     |               |                                                                       |
|                                                                         | Minimal compression and no humidification                       |                                                                       |
|                                                                         |               |                                                                       |
|                                                                         | Cyclical non-contact compression with humidification             |                                                                       |

![Figure 1. Types of topical oxygen devices.](image-url)
The Topical Wound Oxygen (TWO\textsubscript{2}) system differs from other devices in that it applies cyclically pressurized (10–50 mb) pure oxygen within a disposable extremity chamber connected to a stationary oxygen concentrator. Humidity can be added to the system if required. The benefit of this approach is that the higher pressure gradient (pO\textsubscript{2}) results in oxygen molecules diffusing deeper into the hypoxic wound tissue to enhance multiple molecular and enzymatic functions [20,23]. Within the extremity chamber containing pure O\textsubscript{2} at sea level (760 mmHg), the pO\textsubscript{2} can be cyclically pressurized up to nearly 800 mmHg that optimizes enzymatic activity as previously discussed [8]. The cyclical pressure applied with TWO\textsubscript{2} of between 8 mmHg and 38 mmHg creates sequential non-contact compression of the limb that also helps to reduce peripheral edema, and thereby, stimulate wound site perfusion further [24,25]. Several prospective clinical studies have been successfully conducted using this device on both VLUs as well as DFUs [25–27].

3. Topical Oxygen Effect on Wound Healing—The Evidence

In the last several decades there have been several case series and reviews suggesting the putative benefits of topical oxygen administration to expedite healing of chronic wounds [7,11,19,21,28–30]. Perhaps the most compelling early evidence for a topical oxygen wound healing signal was presented in the pre-clinical animal study by Fries et al. published in 2005 [20]. A series of excisional dermal wounds in pigs were created; half of the wounds were subjected to topical oxygen therapy whereas matched control wounds were exposed to ambient air. In one set of experiments, an O\textsubscript{2} electrode was placed at a 2 mm depth in the center of the wound bed. After an exposure of just 4 min, the central superficial wound pO\textsubscript{2} of 11 mmHg increased four-fold to levels of 40 mmHg. Topical O\textsubscript{2} was administered for 7 consecutive days and then stopped. Wound site pO\textsubscript{2} was then measured on day 22, showing a sustained and significantly higher pO\textsubscript{2} in the treated wounds compared to controls. Repeated treatment accelerated wound closure. Histological studies revealed that oxygen-treated wounds showed a stronger presence of VEGF at 7 days, signs of improved angiogenesis at 16 days, and, at day 22, advanced tissue remodeling with normal architecture and healing in the treated group compared to control wounds on the same animals [20]. In a subsequent human study, this same group found that TOT significantly improved wound healing and, in these wounds, there was a significantly higher VEGF expression compared to non-healing wounds [19]. Interestingly, they did not find a significant increase in VEGF expression in those patients treated with HBOT. Similar increases in VEGF and other cytokines in healers vs. non-healers were reported more recently in patients treated with CDO [14,31].

An increasing number of prospective (as well as retrospective), comparative clinical studies have provided the translational evidence necessary to support the efficacy of TOT in conjunction with the standard of care for healing chronic wounds [7]. Although most clinical research has focused on DFUs, several prospective, comparative cohort studies have also shown significantly improved healing of VLUs using cyclical pressurized TWO\textsubscript{2}. One non-randomized study of 83 VLU patients measured the effect of TWO\textsubscript{2} compared to conventional compression dressings (CCD) [24]. At 12 weeks, 80% of TWO\textsubscript{2} managed ulcers were completely healed compared to 35% of the CCD managed ulcers. These same authors later conducted another VLU non-randomized comparative study that similarly investigated the efficacy of TWO\textsubscript{2} vs. CCD in the management of refractory non-healing venous ulcers (RVU) with a duration of at least two years [25]. At 12 weeks, 76% of the TWO\textsubscript{2} managed ulcers had completely healed, compared to 46% of the CCD-managed ulcers with a median time to full healing of 57 days and 107 days, respectively. No other formal VLU studies using TOT have been published to date.

In 2010, a small, prospective, non-blinded, non-randomized study was conducted to examine the clinical efficacy of topical wound oxygen therapy in healing ambulatory DFU patients [26]. Patients were simply allocated to the topical oxygen if a unit (TWO\textsubscript{2}) was available or were otherwise treated with advanced moist wound therapy. At 12 weeks 82.4% of the ulcers in the active therapy arm and 45.5% in the control standard of care arm
had healed completely ($p = 0.04$). The median time to complete healing was 56 days in the TWO$_2$ therapy arm and 93 days in the control standard of care arm ($p = 0.0013$).

A very small, preliminary single center RCT of 17 DFU patients, comparing those treated with a CDO device plus standard of care (SOC) with those treated with standard of care alone, was published in 2013 [17]. This study, where patients were followed for only four weeks, indicated that the topical oxygen group achieved an average wound size reduction of 87% compared to 46% in the standard of care group ($p < 0.05$). While significant wound sample macrophage and inflammatory cytokine level changes (IL-6, IL-8, MMP-1, and MMP-2) were noted in the active CDO group, these patients were not followed until complete healing and the sample size was too small to be widely generalizable [17].

Several years later, the results of the formal sham controlled, multicenter RCT using this same CDO device (EpiFlo) on University of Texas (UT) 1A category DFUs was published [16]. For the primary endpoint of complete healing at 12 weeks in the intention-to-treat (ITT) population ($n = 128$), 53.8% of active CDO patients healed compared to 49.2% of the control sham plus SOC patients ($p = 0.42$). While otherwise a generally well conducted trial, per protocol and other ad hoc sub-analyses also failed to show significantly improved healing rates over those seen in the SOC group [16].

In contrast, the pivotal trial of another CDO device (TransCu O$_2$) reported significantly positive results in their 12-week, multicenter, blinded, placebo ( sham) controlled, parallel group clinical trial [18]. Enrolling patients with UT class 1A ulcers of at least 30 days duration, patients first went through a two week run-in period of standard care. Randomizing 146 patients considered for ITT analysis, the primary outcome again was the percent of patients in each group achieving complete healing at 12 weeks. They reported that 32.4% of CDO treated patients completely healed compared to 17.7% of sham control patients that healed (95% CI 1.05 to 3.59, $p = 0.033$). This was a relative performance improvement of 195% compared with the placebo arm. The time to ulcer closure was also shorter in patients who received CDO therapy ($p = 0.015$). Despite a large number of exclusions after initial randomization and nearly 30% dropout rate, their ITT and per protocol (PP) analyses clearly demonstrated that their topical oxygen device healed significantly more DFU at 12 weeks than those treated by standard care alone [18].

Serena et al. very recently reported on their multicenter RCT comparing another CDO device (Natrox) against good standard of care for the healing of chronic DFUs [15]. This 12 week study, open-label and unblinded, uniquely randomized 145 patients with chronic DFU to either SOC, using primarily a total contact cast (TCC), or to the active TOT group plus SOC/TCC. With a primary outcome of complete healing at 12 weeks and intention-to-treat analysis, 18/64 (28.1%) patients healed in the SOC group at 12 weeks compared with 36/81 (44.4%) in the SOC plus TOT group ($p = 0.044$). In the PP population (those completing $\geq$ 8 visits), there was a statistically significant reduction in wound area between the groups: the SOC group saw a mean reduction of 40% compared to the SOC plus TOT group mean reduction of 70% ($p = 0.005$). Partially conducted amid the coronavirus pandemic, this study had a 19% withdrawal rate. Nonetheless, this community-based study has demonstrated that TOT can lead to a statistically significant improvement in healing rates in patients with DFUs that are resistant to healing with optimal SOC alone [15].

Studying home-based, cyclical pressurized topical wound oxygen (TWO$_2$) for the healing of recalcitrant DFUs, a rather robust multicenter, multinational, sham controlled, double-blinded RCT was recently reported by Frykberg et al. [27]. Using a group sequential design with a priori stopping points and optimal SOC throughout, the active TWO$_2$ arm was found to be superior to the sham arm, with a closure rate of 41.7% at 12 weeks compared with 13.5% ($p = 0.007$), respectively. Favoring those treated with the active therapy, this difference in outcome produced an odds ratio (OR) of 4.57 (97.8% CI 1.19, 17.57, $p = 0.010$). Cox proportional hazards modeling, after adjustment for UT grade, demonstrated $>4.5$ times the likelihood to heal DFUs over 12 weeks compared with the sham arm with a hazard ratio (HR) of 4.66 (97.8% CI 1.36, 15.98, $p = 0.004$). Furthermore, they found that 56% of TWO$_2$ patients achieved 100% healing at 12 months vs. 27% in
the sham arm, (p = 0.013) and only a 5% amputation rate at one year from enrollment. As found in other TOT cohort and randomized trials, this sham controlled, double-blind RCT demonstrated that, at both 12 weeks and 12 months, adjunctive cyclical pressurized TWO₂ therapy was superior in healing chronic DFUs compared with optimal SOC alone [27].

This same device has subsequently been investigated to examine the real-world impact of TWO₂ on hospitalizations and amputations in patients with diabetic foot ulcers (DFU) compared to patients who had not used TWO₂. An, as of yet, unpublished retrospective, comparative cohort study of 202 DFU patients found that 6.6% and 12.1% of TWO₂ patients had hospitalizations and amputations at one year, respectively, compared to 54.1% and 41.4% of patients who had not used adjunctive TWO₂ (p < 0.0001, p < 0.0001), representing 88% and 71% reductions [32]. Although this data is still subject to peer review, it infers that treating DFU patients with TWO₂ can lead to significant reductions in hospitalizations and amputations in the real-world setting.

Two recent systematic reviews with meta-analyses have further added support to the clinical effectiveness of topical oxygen therapy for healing chronic DFUs [33,34]. Although not without some methodological deficiencies and heterogeneity, they both indicate that TOT (using CDO devices as well as cyclical pressurized devices) can augment wound healing among persons with chronic diabetic foot ulcers. Although the exact location of the wounds being treated in these studies was not specified, most were on the plantar surfaces. Hence, appropriate offloading was a critical component of standard of care in both assignment groups within each study. Thanigaimani et al., reviewing all but the most recent 2021 TOT trial, indicated that their meta-analysis also suggests that TOT improves the likelihood of DFU healing [34]. However, not having the data cited above on amputations nor cost-effectiveness data, they could not make further suggestions regarding these outcomes.

4. Conclusions

From the foregoing, it is evident that topical oxygen therapy can no longer be considered an experimental or unproven therapy for the healing of chronic wounds, especially diabetic foot ulcers. The data clearly have demonstrated a significant improvement in the healing of chronic DFUs treated with either CDO devices or pressurized devices (TWO₂) as compared to standard of care alone. That being said, it is also critical to emphasize that TOT (as for any advanced wound therapy) must be administered in conjunction with optimal wound care. Without addressing the basic tenets of wound care (debridement, offloading, treatment of infection, treatment of ischemia, etc.), no therapy can be expected to miraculously heal a chronic wound. Furthermore, not all wounds are suitable for TOT and not all wounds thus treated will heal; this therapy is certainly not a panacea. However, when used adjunctively with optimal wound care, the aforementioned studies provide the clinical evidence necessary to support the use of topical oxygen in the management of chronic DFUs.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: R.G.F has received prior research funding and is a Consultant for AOTI, Ltd. (Galway, Ireland).

References

1. Fischer, B.H. Topical hyperbaric oxygen treatment of pressure sores and skin ulcers. Lancet 1969, 2, 405–409. [CrossRef]
2. Leslie, C.A.; Sapico, F.L.; Ginunas, V.J.; Adkins, R.H. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988, 11, 111–115. [CrossRef] [PubMed]
3. Gottrup, F.; Dissemond, J.; Baines, C.; Frykberg, R.; Jensen, P.O.; Kot, J.; Kroger, K.; Longobardi, P. Use of Oxygen Therapies in Wound Healing. J. Wound Care 2017, 26, S1–S43. [CrossRef]
4. Londahl, M.; Katzman, P.; Nilsson, A.; Hammarlund, C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. *Diabetes Care* **2010**, *33*, 998–1003. [CrossRef] [PubMed]

5. Margolis, D.J.; Gupta, J.; Hoffstad, O.; Papdopoulos, M.; Glick, H.A.; Thom, S.R.; Mitra, N. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: A cohort study. *Diabetes Care* **2013**, *36*, 1961–1966. [CrossRef]

6. Santema, K.T.B.; Steekenbroek, R.M.; Koelemay, M.J.W.; Reekers, J.A.; van Dortmont, L.M.C.; Oomen, A.; Smeets, L.; Wever, J.J.; Legemate, D.A.; Ubbink, D.T.; et al. Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial. *Diabetes Care* **2018**, *41*, 112–119. [CrossRef] [PubMed]

7. de Smet, G.H.J.; Kroese, L.F.; Menon, A.G.; Jeekel, J.; van Pelt, A.W.J.; Kleinrensink, G.J.; Lange, J.F. Oxygen therapies and their effects on wound healing. *Wound Repair Regen.* **2017**, *25*, 591–608. [CrossRef]

8. Oropallo, A.R.; Serena, T.E.; Armstrong, D.G.; Niederauer, M.Q. Molecular Biomarkers of Oxygen therapy in Patients with Diabetic Foot Ulcers. *Biomolecules* **2021**, *11*, 925. [CrossRef]

9. Dunnill, C.; Patton, T.; Brennan, J.; Barrett, J.; Dryden, M.; Cooke, J.; Leaper, D.; Georgopoulos, N.T. Reactive oxygen species (ROS) and wound healing: The functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. *Int. Wound J.* **2017**, *14*, 89–96. [CrossRef]

10. Sen, C.K. Wound healing essentials: Let there be oxygen. *Wound Repair Regen.* **2009**, *17*, 1–18. [CrossRef]

11. Gordillo, G.M.; Sen, C.K. Evidence-based recommendations for the use of topical oxygen therapy in the treatment of lower extremity wounds. *Int. J. Low Extrem. Wounds* **2009**, *8*, 105–111. [CrossRef]

12. Wattel, E.; Mathieu, D. Oxygen and wound healing. *Bull Acad. Natl. Med.* **2005**, *189*, 853–864; discussion 864–855.

13. Dissemond, J.; Kroger, K.; Storck, M.; Risse, A.; Engels, P. Topical oxygen wound therapies for chronic wounds: A review. *J Wound Care* **2015**, *24*, 53–63. [CrossRef]

14. Niederauer, M.Q. How can we deliver oxygen to wounds? *J Wound Care* **2021**, *30*, S3–S4. [CrossRef] [PubMed]

15. Sen, C.K. Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. *Ostomy Wound Manag.* **2013**, *59*, 19–26.

16. Driver, V.R.; Yao, M.; Kantarcı, A.; Gu, G.; Park, N.; Hasıtkur, H. A prospective, randomized clinical study evaluating the effect of transdermal continuous oxygen delivery to moist Wound Therapy for the treatment of Diabetic Foot Ulcers. *Ostomy Wound Manag.* **2017**, *63*, 12–28.

17. Driver, V.R.; Reyzelman, A.; Kawalec, J.; French, M. A Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers. *Ostomy Wound Manag.* **2013**, *59*, 19–26.

18. Niederauer, M.Q.; Michalek, J.E.; Liu, Q.; Papas, K.K.; Lavery, L.A.; Armstrong, D.G. Continuous diffusion of oxygen improves diabetic foot ulcer healing when compared with a placebo control: A randomised, double-blind, multicentre study. *J Wound Care* **2018**, *27*, S30–S45. [CrossRef] [PubMed]

19. Gordillo, G.M.; Roy, S.; Kanna, S.; Schlanger, R.; Kandelwal, S.; Phillips, G.; Sen, C.K. Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. *Clin. Exp. Pharmacol. Physiol.* **2008**, *35*, 957–964. [CrossRef]

20. Fries, R.B.; Wallace, W.A.; Roy, S.; Kuppusamy, P.; Bergdall, V.; Gordillo, G.M.; Melvin, W.S.; Sen, C.K. Dermal excisional wound healing in pigs following treatment with topically applied pure oxygen. *Mutat. Res.* **2005**, *579*, 172–181. [CrossRef] [PubMed]

21. Kalliainen, L.K.; Gordillo, G.M.; Schlanger, R.; Sen, C.K. Topical oxygen as an adjunct to wound healing: A clinical case series. *Pathophysiology* **2003**, *9*, 81–87. [CrossRef]

22. Copeland, K.; Purvis, A.R. A Retrospective Chart Review of Chronic Wound Patients Treated with Topical Oxygen Therapy. *Adv. Wound Care (New Rochelle)* **2017**, *6*, 143–152. [CrossRef]

23. Ladizinsky, D.; Roe, D. New Insights Into Oxygen Therapy for Wound Healing. *Wounds* **2010**, *22*, 294–300. [PubMed]

24. Tawfick, W.; Sultan, S. Does topical wound oxygen (TWO2) offer an improved outcome over conventional compression dressings (CCD) in the management of refractory venous ulcers (RVU)? A parallel observational comparative study. *Eur. J. Vasc. Endovasc. Surg.* **2009**, *38*, 125–132. [CrossRef] [PubMed]

25. Tawfick, W.A.; Sultan, S. Technical and clinical outcome of topical wound oxygen in comparison to conventional compression dressings in the management of refractory nonhealing venous ulcers. *Vasc. Endovasc. Surg.* **2013**, *47*, 30–37. [CrossRef] [PubMed]

26. Blackman, E.; Moore, C.; Hyatt, J.; Railton, R.; Frye, C. Topical wound oxygen therapy in the treatment of severe diabetic foot ulcers: A prospective controlled study. *Ostomy Wound Manag.* **2010**, *56*, 24–31.

27. Frykberg, R.G.; Franks, P.J.; Edmonds, M.; Brantley, J.N.; Teot, L.; Wild, T.; Garoufalias, M.G.; Lee, A.M.; Thompson, J.A.; Reach, G.; et al. A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study. *Diabetes Care* **2020**, *43*, 616–624. [CrossRef]

28. Gordillo, G.M.; Schlanger, R.; Wallace, W.A.; Bergdall, V.; Bartlett, R.; Sen, C.K. Protocols for topical and systemic oxygen treatments in wound healing. *Methods Enzymol.* **2004**, *381*, 575–585. [CrossRef]

29. Gordillo, G.M.; Hunt, T.K.; Sen, C.K. Significance of oxygen therapeutics. *Wound Repair Regen.* **2003**, *11*, 393. [CrossRef]
30. Gordillo, G.M.; Sen, C.K. Revisiting the essential role of oxygen in wound healing. *Am. J. Surg.* 2003, 186, 259–263. [CrossRef]
31. Lavery, L.A.; Killeen, A.L.; Farrar, D.; Akgul, Y.; Crisologo, P.A.; Malone, M.; Davis, K.E. The effect of continuous diffusion of oxygen treatment on cytokines, perfusion, bacterial load, and healing in patients with diabetic foot ulcers. *Int. Wound J.* 2020, 17, 1986–1995. [CrossRef] [PubMed]
32. Yellin, J.I.; Gaebler, J.A.; Zhou, F.F.; Niecko, T.; Novins, O.; Ockert, A.; Krzynowek, D.; Garoufalis, M.G.; Lee, A.M.; Frykberg, R.G. Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real World Outcomes. 2021; submit.
33. Nataraj, M.; Maity, A.G.; Karkada, G.; Hande, M.; Rodrigues, G.S.; Shenoy, R.; Prasad, S.S. Application of Topical Oxygen Therapy in Healing Dynamics of Diabetic Foot Ulcers—A Systematic Review. *Rev. Diabet. Stud.* 2019, 15, 74–82. [CrossRef]
34. Thanigaimani, S.; Singh, T.; Golledge, J. Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis. *Diabet. Med.* 2021, e14585. [CrossRef]